ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2057

Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)

Meghan Nelson1, Colleen Mosley2, D. Sofia Villacis-Nunez3, Kelly Rouster-Stevens3 and Amit Thakral3, 1Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children's Healthcare of Atlanta, Atlanta, GA, 2Children’s Healthcare of Atlanta, Atlanta, GA, 3Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that is associated with significant disease damage, morbidity, and mortality. In comparison to the adult population, childhood onset SLE (cSLE) tends to be more aggressive given the higher preponderance of renal and neuropsychiatric disease and increased disease activity. There is a paucity of literature examining relationship between disease activity, follow up, and health care utilization. The objective of this study is to determine whether early identification of those at risk for loss to follow up would affect compliance with follow-up visits and disease morbidity in patients with childhood-onset systemic lupus erythematosus (cSLE).

Methods: Between July 2021 and January 2022 charts of patients < 18 years of age with SLE who met Systemic Lupus International Collaborative Clinics (SLICC) classification criteria were surveilled and those who were not evaluated in clinic in the previous 120-day period were eligible for inclusion. Identified patients were added to a follow up list and subsequently contacted via telephone for re-establishing care within the month, if eligible.Through retrospective chart review, we assessed disease activity (SLE Disease Activity Index) at last clinic visit. Patients were stratified into two cohorts of lower and higher disease activity, with SLE disease activity index (SLEDAI) < 4 and SLEDAI ≥ 4, respectively. Clinical, epidemiological and serological data, as well as markers of disease morbidity including hospitalizations and Emergency Department (ED) visits were reviewed and compared between the two groups using Fisher exact test for categorical variables and Wilcoxon test for continuous variables.

Results: Forty-one patients were included, of which 34 (83%) were female. Median age was 14 years. Statistically significant differences were identified between the groups, to include age at diagnosis (p< 0.001) associated with higher current SLEDAI score. Of the patients reviewed, participants met an average of 4.6/13 SLICC criteria at diagnosis, with several of these criteria noted to be statistically significant between groups (Table 1). Time to follow up (p< 0.001), high dose prednisone use (p=0.04), hospitalizations (p< 0.001) and ED visits (p< 0.001) were found to be associated with higher SLEDAI scores.

Conclusion: Our findings suggest that cSLE patients with current higher disease activity are at risk for disease related morbidity in the setting of follow-up non-adherence. While further studies are required to enhance our understanding of this association, this links the importance of disease-related outcome and outpatient follow-up visits in this particularly vulnerable patient population.

Supporting image 1

Table 1: Characteristics of cSLE stratified by SLEDAI. This table depicts the patient demographics, clinical features and management of pediatric systemic lupus erythematosus patients for patients stratified be SLEDAI score.


Disclosures: M. Nelson, None; C. Mosley, None; D. Villacis-Nunez, None; K. Rouster-Stevens, Accordant; A. Thakral, None.

To cite this abstract in AMA style:

Nelson M, Mosley C, Villacis-Nunez D, Rouster-Stevens K, Thakral A. Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/outpatient-visit-adherence-and-impact-on-disease-related-morbidity-in-childhood-onset-systemic-lupus-erythematosus-csle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outpatient-visit-adherence-and-impact-on-disease-related-morbidity-in-childhood-onset-systemic-lupus-erythematosus-csle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology